Acalculous Cholecystitis Complicated by Liver Abscess as a Manifestation of Cholesterol Embolization Syndrome – Infrequent Manifestation Precipitated by a Common Procedure

  • Ossama Maadarani Internal Medical Department, Ahmadi Hospital – Kuwait Oil Company, Kuwait
  • Hany Alfayed Internal Medicine Department, Ahmadi Hospital - Kuwait Oil Company, Kuwait
  • Zouheir Bitar Internal Medicine Department, Ahmadi Hospital - Kuwait Oil Company, Kuwait
  • Moataz Daher Internal Medicine Department, Ahmadi Hospital - Kuwait Oil Company, Kuwait
  • Tamer Zaalouk Internal Medicine Department, Ahmadi Hospital - Kuwait Oil Company, Kuwait
  • Mohamed Abdelfatah Internal Medicine Department, Ahmadi Hospital - Kuwait Oil Company, Kuwait

Keywords

Cholesterol crystals, acalculous cholecystitis, liver abscess

Abstract

Cholesterol embolization syndrome (CES) is an atherosclerotic complication affecting different systems with various clinical manifestations, usually triggered iatrogenically by interventional and surgical procedures or thrombolytic therapy, although spontaneous cases have been reported. The hepatobiliary system can also be affected when the showered cholesterol crystals obliterate small vessels within this system causing both ischaemic and inflammatory responses. We describe a case of a male patient who initially developed multiple lacunar cerebral infarcts 10 days post-thrombolytic therapy and percutaneous coronary intervention (PCI) due to acute myocardial infarction. Several weeks later he developed acalculous cholecystitis complicated by liver abscess and kidney injury. The consequences and latency of manifestations within different organs and the temporal relationship with well-known trigger factors raised the suspicion of CES.

VIEW THE ENTIRE ARTICLE

References

Kronzon I, Saric M. Cholesterol embolization syndrome. Circulation 2010;122:631–641.

Quinones A, Saric M. The cholesterol emboli syndrome in atherosclerosis. Curr Atheroscler Rep 2013;15(4):315.

Moolenaar W, Lamers CB. Cholesterol crystal embolization in the Netherlands. Arch Intern Med 1996;156:653–657.

Scolari F, Ravani P, Pola A, Guerini S, Zubani R, Movilli E, et al. Predictors of renal and patient outcomes in atheroembolic renal disease: a prospective study. J Am Soc Nephrol 2003;14:1584–1590.

Hitti WA, Wali RK, Weinman EJ, Drachenberg C, Briglia A. Cholesterol embolization syndrome induced by thrombolytic therapy. Am J Cardiovasc Drugs 2008;8(1):27–34.

Ezzeddine MA, Primavera JM, Rosand J, Hedley-Whyte ET, Rordorf G. Clinical characteristics of pathologically proved cholesterol emboli to the brain. Neurology 2000;54:1681–1683.

Moolenaar W, Lamers CB. Gastrointestinal blood loss due to cholesterol crystal embolization. J Clin Gastroenterol 1995;21(3):220.

Fine MJ, Kapoor W, Falanga V. Cholesterol crystal embolization: a review of 221 cases in the English literature. Angiology 1987;38:769–784.

Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al.; AHA/ACC, National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113(19):2363–2372.

Yonemura K, Ikegaya N, Fujigaki Y, Suzuki H, Togawa A, Hishida A. Potential therapeutic effect of simvastatin on progressive renal failure and nephrotic-range proteinuria caused by renal cholesterol embolism. Am J Med Sci 2001;322:50–52.

Published: 2020-10-02

Issue: LATEST ONLINE (view)

Section: Articles

How to cite:
1.
Maadarani O, Alfayed H, Bitar Z, Daher M, Zaalouk T, Abdelfatah M. Acalculous Cholecystitis Complicated by Liver Abscess as a Manifestation of Cholesterol Embolization Syndrome – Infrequent Manifestation Precipitated by a Common Procedure. EJCRIM 2020;2 doi:10.12890/2020_001953.